Figures, data, facts after 4,800 patients
The da Vinci®-system prostatectomy is an effective minimally-invasive procedure for the surgical therapy of prostate carcinoma:
| Oncologically safe procedure | yes |
| NeuroSAFE frozen section technique possible in all patients | yes |
| Minimally-Invasive Operation | yes |
| Continence one year post operation* | 91 - 97 % |
| Erectile function sufficient for sexual intercourse* | 85 - 95 % |
| Average blood loss | 150 mL |
| Blood transfusion rate | 1,2 % |
| Average hospital stay | 7 Days |
Continence
With da Vinci®-prostatectomies at the Martini-Klinik the long-term continence can be granted for 91 – 97 % of all patients. According to the BARMER GEK Report 2012, these results exceed the German average by 20 – 26 %.
| < 60 years | 60 - 70 years | > 70 years | ||||
|---|---|---|---|---|---|---|
| Pads per 24 h [#] | Bilateral nerve preservation [%] | Unilateral nerve preservation [%] | Bilateral nerve preservation [%] | Unilateral nerve preservation [%] | Bilateral nerve preservation [%] | Unilateral nerve preservation [%] |
| 0 - 1 "for security" | 95,9 | 97,3 | 95,0 | 91,2 | 91,1 | 94,4 |
| 1 - 2 | 4,1 | 2,7 | 3,9 | 7,0 | 6,7 | 0,0 |
| 3 - 5 | 0,0 | 0,0 | 1,1 | 1,8 | 2,2 | 5,6 |
Nerve-sparing operation technique and post-operative erectile function
Nerve-sparing operations on over 98 % of all prostate carcinoma contained within the organ are possible with da Vinci®-prostatectomies at the Martini-Klinik. According to the BARMER GEK Report 2012, this is more than double as frequent than the German average.
Successfully completed nerve-sparing procedures in percent
| pT2-tumors (tumor is contained within the prostate) | pT3a-tumors (tumor spreads through the prostate capsule) | pT3b-tumors (tumor spreads to seminal vesicles) in percent |
|---|---|---|
| 98,6 | 93,0 | 32,7 |
Da Vinci®-prostatectomies performed at our center leads to a retention of potency for up to 94.7 % of our patients. The rates for bilateral nerve preservation and younger patients are better than those for unilateral nerve preservation and older patients.
Sexual intercourse possible, in percent
| < 55 years | 55 - 65 years | > 65 years | |||
|---|---|---|---|---|---|
| Bilateral nerve preservation | Unilateral nerve preservation | Bilateral nerve preservation | Unilateral nerve preservation | Bilateral nerve preservation | Unilateral nerve preservation |
| 94,7 | 80,0 | 71,6 | 62,2 | 66,7 | 58,3 |
Approximately 20 % of the surveyed patients used erection enhancing medication (Viagra, Cialis or Levita). Data recorded:1 year after the operation. Patients with good pre-operative erectile function considered.
Tumor-free incision margins (using NeuroSafe frozen section technique)
Tumor-free margins for more than 96 % of patients.
Tumor-free margins in percent
pT2-tumors (tumor is contained within the prostate) | pT3a-tumors (tumor spreads through the prostate capsule) | pT3b-tumors (tumor spreads to seminal vesicles) |
|---|---|---|
| 96,0 | 83,3 | 48,7 |
Each year we evaluate 15,000 questionnaires!
After a week, three months and subsequently year for year we ask each patient about the condition of his health and the quality of his life.
These results are the product of diligent data analysis which our patients send back to us. They thus reflect the distinguished quality of results achieved at the Martini-Klinik. These results were and are consistently updated in order to inform our patients of the current success rates of da Vinci robot-assisted prostatectomies. Furthermore, the regular updating of the results facilitates the ongoing further development and refinement of the operative therapy of prostate cancer at the Martini-Klinik.
As the development of the clinical and pathological data is an ongoing and continuous process, the results are dynamic and may vary from the current data in subsequent evaluations.
